Denna sida på svenska

Hareth Nahi

Senior researcher

Visiting address : M54 ; Karolinska Universitetssjukhuset, 141 86 Stockholm, Sweden
Delivery address : , Sweden

Publications

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice
Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, et al
American journal of hematology 2016;91(6):575-80

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Usmani Sz, Weiss Bm, Plesner T, Bahlis Nj, Belch A, Lonial S, et al
Blood 2016;128(1):37-44

Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden
Borg S, Nahi H, Hansson M, Lee D, Elvidge J, Persson U
Acta oncologica (Stockholm, Sweden) 2016;55(5):554-60

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Dimopoulos Ma, Oriol A, Nahi H, San-miguel J, Bahlis Nj, Usmani Sz, et al
The New England journal of medicine 2016;375(14):1319-1331

Genome-wide association study identifies multiple susceptibility loci for multiple myeloma
Mitchell Js, Li N, Weinhold N, Försti A, Ali M, Van Duin M, et al
Nature communications 2016;7():12050-

Health resource utilization associated with skeletal-related events: results from a retrospective European study
Body Jj, Pereira J, Sleeboom H, Maniadakis N, Terpos E, Acklin Yp, et al
The European journal of health economics : HEPAC : health economics in prevention and care 2016;17(6):711-21

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau P, Masszi T, Grzasko N, Bahlis Nj, Hansson M, Pour L, et al
The New England journal of medicine 2016;374(17):1621-34

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009
Rosengren S, Mellqvist Uh, Nahi H, Forsberg K, Lenhoff S, Strömberg O, et al
Bone marrow transplantation 2016;():-

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Moreau P, Van De Donk Nw, San Miguel J, Lokhorst H, Nahi H, Ben-yehuda D, et al
Drugs 2016;76(8):853-67

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (vol 76, pg 853, 2016)
Moreau P, Van De Donk Nwcj, Miguel Js, Lokhorst H, Nahi H, Ben-yehuda D, et al
DRUGS 2016;76(9):989-990

Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21
Nahi H, Våtsveen Tk, Lund J, Heeg Bm, Preiss B, Alici E, et al
European journal of haematology 2016;96(1):46-54

Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach
Alici E, Chrobok M, Lund J, Ahmadi T, Khan I, Duru Ad, et al
British journal of haematology 2016;174(3):473-7

THE SWEDISH MULTIPLE MYELOMA REGISTER: MEDIAN 5-YEAR SURVIVAL OF 7.3 YEARS IN PATIENTS 65 YEARS AND YOUNGER, POPULATION-BASED DATA ON 3,876 MULTIPLE MYELOMA PATIENTS DIAGNOSED 2008-2013
Blimark Ch, Genell A, Juliusson G, Nahi H, Forsberg K, Turesson I, et al
HAEMATOLOGICA 2016;:522-522

This abstract is part of the Presidential Symposium AN OPEN-LABEL, RANDOMISED, PHASE 3 STUDY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): POLLUX
Dimopoulos Ma, Oriol A, Nahi H, Miguel Js, Bahlis Nj, Rabin N, et al
HAEMATOLOGICA 2016;:342-342

Treosulfan plus fludarabine - encouraging conditioning for allogeneic hematopoietic stem cell transplantation in multiple myeloma
Afram G, Nahi H, Liwing J, Heeg B, Mattsson J, Leblanc K, et al
BONE MARROW TRANSPLANTATION 2016;:S592-S592

A genealogical and clinical study of the phenotypical variation within the Swedish transthyretin His88Arg (p. His108Arg) amyloidosis family
Hellman U, Lundgren He, Westermark P, Stafberg C, Nahi H, Tachlinski S, et al
European journal of medical genetics 2015;58(4):211-5

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, et al
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2015;21(12):2039-51

A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
Hansson M, Gimsing P, Badros A, Niskanen Tm, Nahi H, Offner F, et al
Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21(12):2730-6

ASSESSING THE BENEFIT OF CONTINUOUS TREATMENT IN THE FIRST TRIAL (MM-020): IMPACT OF RESPONSE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
Bahlis N, Corso A, Mugge Lo, Shen Zx, Desjardins P, Stoppa Am, et al
HAEMATOLOGICA 2015;:85-86

Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT
Grövdal M, Nahi H, Gahrton G, Liwing J, Waage A, Abildgaard N, et al
Bone marrow transplantation 2015;50(6):808-12

CAN OVERALL SURVIVAL BE IMPROVED IN ELDERLY MULTIPLE MYELOMA PATIENTS?
Heeg Bm, Liwing J, Karstorp S, Postma M, Silvennoinen R, Putkonen M, et al
HAEMATOLOGICA 2015;:517-517

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Aspire Investigators, Stewart Ak, Rajkumar Sv, Dimopoulos Ma, Masszi T, Spicka I, et al
NEW ENGLAND JOURNAL OF MEDICINE 2015;372(2):142-52

Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
Usmani S, Weiss B, Bahlis Nj, Belch A, Lonial S, Lokhorst H, et al
BLOOD 2015;126(23):-

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
Duru Ad, Sutlu T, Wallblom A, Uttervall K, Lund J, Stellan B, et al
PloS one 2015;10(9):e0138248-

IS A DEEP RESPONSE THE KEY TO SUCCESSFUL TREATMENT OF MULTIPLE MYELOMA?
Liwing J, Heeg Bm, Karstorp S, Postma M, Silvennoinen R, Putkonen M, et al
HAEMATOLOGICA 2015;:92-92

Multiple Myeloma patients with del(8)(p21) are more resistant to Bortezomib treatment
Duru Ad, Sutlu T, Wallblom A, Uttervall K, Lund J, Stellan B, et al
BONE MARROW TRANSPLANTATION 2015;:S17-S17

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)
Dimopoulos Ma, Grosicki S, Jedrzejczak Ww, Nahi H, Gruber A, Hansson M, et al
BLOOD 2015;126(23):-

Re-Challenging with Anti-CD38 Monotherapy in Triple-Refractory Multiple Myeloma Patients Is a Feasible and Safe Approach
Lund J, Alici E, Chrobok M, Gruber A, Ahmadi T, Khan I, et al
BLOOD 2015;126(23):-

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst Hm, Plesner T, Laubach Jp, Nahi H, Gimsing P, Hansson M, et al
The New England journal of medicine 2015;373(13):1207-19

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex
Lund J, Karstorp S, Alici E, Gruber A, Lauri B, Blimark C, et al
BLOOD 2015;126(23):-

TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome
Falk Ij, Willander K, Chaireti R, Lund J, Nahi H, Hermanson M, et al
European journal of haematology 2015;94(4):355-62

TRIAL EFFICACY VS REAL WORLD EFFECTIVENESS IN FIRST LINE TREATMENT OF MULTIPLE MYELOMA
Liwing J, Heeg Bm, Karstorp S, Postma M, Silvennoinen R, Putkonen M, et al
HAEMATOLOGICA 2015;:512-513

Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma
Swaminathan B, Thorleifsson G, Jöud M, Ali M, Johnsson E, Ajore R, et al
Nature communications 2015;6():7213-

Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients
Lund J, Uttervall K, Liwing J, Gahrton G, Alici E, Aschan J, et al
European journal of haematology 2014;92(1):19-25

Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement
Nahi H, Svedmyr E, Lerner R
European journal of haematology 2014;92(5):454-5

Bortezomib Re-treatment in Patients with Multiple Myeloma (MM). A Real World Medical Practice Experience from a Swedish National Registry
Thilakarathne P, Diels J, Van Sanden S, Liwing J, Chirita O, Van Agthoven M, et al
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2014;17(7):A617-

BORTEZOMIB RE-TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA (MM). A REAL WORLD MEDICAL PRACTICE EXPERIENCE FROM A SWEDISH NATIONAL REGISTRY
Thilakarathne P, Diels J, Van Sanden S, Liwing J, Chirita O, Van Agthoven M, et al
VALUE IN HEALTH 2014;17(7):A617-A617

Comparative Real World Effectiveness of Novel Agents Versus Conventional Therapies in Multiple Myeloma Patients in Sweden
Thilakarathne P, Diels J, Van Sanden S, Liwing J, Van Agthoven M, Chirita O, et al
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2014;17(7):A545-6

COMPARATIVE REAL WORLD EFFECTIVENESS OF NOVEL AGENTS VERSUS CONVENTIONAL THERAPIES IN MULTIPLE MYELOMA PATIENTS IN SWEDEN
Thilakarathne P, Diels J, Van Sanden S, Liwing J, Van Agthoven M, Chirita O, et al
VALUE IN HEALTH 2014;17(7):A545-A546

Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).
Lokhorst Hm, Laubach J, Nahi H, Plesner T, Gimsing P, Hansson M, et al
JOURNAL OF CLINICAL ONCOLOGY 2014;32(15):-

DOSE-DEPENDENT EFFICACY OF DARATUMUMAB (DARA) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RR MM)
Lokhorst H, Laubach J, Nahi H, Plesner T, Gimsing P, Hansson M, et al
HAEMATOLOGICA 2014;:106-107

EFFECTS OF SINGLE-AGENT BORTEZOMIB (BTZ) AS POST-TRANSPLANT CONSOLIDATION ON MULTIPLE MYELOMA (MM)-RELATED BONE DISEASE: FIRST RESULTS FROM A MULTICENTER, RANDOMIZED PHASE 2 STUDY
Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, et al
HAEMATOLOGICA 2014;:362-362

European perspective on multiple myeloma treatment strategies in 2014
Ludwig H, Sonneveld P, Davies F, Bladé J, Boccadoro M, Cavo M, et al
The oncologist 2014;19(8):829-44

Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype
Jakobsen Falk I, Fyrberg A, Paul E, Nahi H, Hermanson M, Rosenquist R, et al
British journal of haematology 2014;167(5):671-80

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial
Bahlis Nj, Corso A, Mugge Lo, Shen Zx, Desjardins P, Stoppa Am, et al
BLOOD 2014;124(21):-

Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population
Liwing J, Uttervall K, Lund J, Aldrin A, Blimark C, Carlson K, et al
British journal of haematology 2014;164(5):684-93

IMWG consensus on risk stratification in multiple myeloma
Int Myeloma Working Grp, Chng Wj, Dispenzieri A, Chim Cs, Fonseca R, Goldschmidt H, et al
LEUKEMIA 2014;28(2):269-77

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
First Trial Team, Benboubker L, Dimopoulos Ma, Dispenzieri A, Catalano J, Belch Ar, et al
NEW ENGLAND JOURNAL OF MEDICINE 2014;371(10):906-17

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
San-miguel Jf, Hungria Vt, Yoon Ss, Beksac M, Dimopoulos Ma, Elghandour A, et al
The Lancet. Oncology 2014;15(11):1195-206

THE REVII TRIAL: LENALIDOMIDE AND DEXAMETHASONE AS SECOND LINE TREATMENT IN MYELOMA FOLLOWED BY EXTENDED LENALIDOMID VS LEN/DEX
Lund J, Gruber A, Lauri B, Blimark C, Swedin A, Hansson M, et al
HAEMATOLOGICA 2014;:104-105

The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment
Uttervall K, Duru Ad, Lund J, Liwing J, Gahrton G, Holmberg E, et al
PloS one 2014;9(7):e101819-

Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT)
Heeg B, Van Agthoven M, Van Beurden-tan C, Liwing J, Mellqvist Uh, Plesner T, et al
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2014;17(7):A617-8

TREATMENT SEQUENCING SURVIVAL MODEL FOR PATIENTS WITH MULTIPLE MYELOMA INELIGIBLE FOR STEM CELL TRANSPLANTATION (SCT)
Heeg B, Van Agthoven M, Van Beurden-tan C, Liwing J, Mellqvist Uh, Plesner T, et al
VALUE IN HEALTH 2014;17(7):A617-A618

A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis
Uttervall K, Admasie J, Alici E, Lund J, Liwing J, Aschan J, et al
Acta haematologica 2013;130(1):7-15

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
Mellqvist Uh, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, et al
Blood 2013;121(23):4647-54

DARATUMUMAB Anti-CD38 Monoclonal Antibody, Treatment of Multiple Myeloma
Richardson P, Lokhorst H, Palumbo A, Nahi H, Laubach J, Gimsing P, et al
DRUGS OF THE FUTURE 2013;38(8):545-554

Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase
Falk Ij, Fyrberg A, Paul E, Nahi H, Hermanson M, Rosenquist R, et al
American journal of hematology 2013;88(12):1001-6

In search of the molecular consequences of 8p21 deletion in multiple myeloma: commentary on Gmidéne et al
Sutlu T, Alici E, Gahrton G, Nahi H
Medical oncology (Northwood, London, England) 2013;30(2):569-

Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma
Lokhorst Hm, Plesner T, Gimsing P, Nahi H, Minnema M, Lassen Un, et al
JOURNAL OF CLINICAL ONCOLOGY 2013;31(15):-

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
Int Myeloma Working Grp, De Larrea Cf, Kyle Ra, Durie Bgm, Ludwig H, Usmani S, et al
LEUKEMIA 2013;27(4):780-91

Real World Data In Myeloma: Experiences From The Swedish Population-Based Registry On 2494 Myeloma Patients Diagnosed 2008-2011
Blimark C, Holmberg E, Juliusson G, Nahi H, Karin F, Turesson I, et al
BLOOD 2013;122(21):-

Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype
Green H, Falk Ij, Lotfi K, Paul E, Hermansson M, Rosenquist R, et al
PHARMACOGENOMICS JOURNAL 2012;12(2):111-8

Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery
Ungerstedt Js, Watz E, Uttervall K, Johansson Bm, Wahlin Be, Näsman P, et al
Medical oncology (Northwood, London, England) 2012;29(3):2191-9

Daratumumab, a CD38 mab, for the treatment of relapsed/refractory multiple myeloma patients: Preliminary efficacy data from a multicenter phase I/II study.
Plesner T, Lokhorst Hm, Gimsing P, Nahi H, Lisby S, Richardson Pgg
JOURNAL OF CLINICAL ONCOLOGY 2012;30(15):-

Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study
Plesner T, Lokhorst H, Gimsing P, Nahi H, Lisby S, Richardson Pg
BLOOD 2012;120(21):-

Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution
Nahi H, Remberger M, Machaczka M, Ungerstedt J, Mattson J, Ringden O, et al
Medical oncology (Northwood, London, England) 2012;29(4):2348-58

Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population
Nahi H, Liwing J, Aldrin A, Andreasson J, Blimark C, Carlson K, et al
BLOOD 2012;120(21):-

Is Renal Impairment Still a Poor Prognostic Marker in Myeloma Care?: A Population Based Study Including 1542 Patients
Uttervall K, Andreasson J, Liwing J, Nasman P, Aschan J, Nahi H
BLOOD 2012;120(21):-

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Int Myeloma Working Grp, Kumar Sk, Lee Jh, Lahuerta Jj, Morgan G, Richardson Pg, et al
LEUKEMIA 2012;26(1):149-57

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (vol 26, pg 149, 2012)
Int Myeloma Working Grp, Kumar Sk, Lee Jh, Lahuerta Jj, Morgan G, Richardson Pg, et al
LEUKEMIA 2012;26(5):1153-1153

Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation
Machaczka M, Nahi H, Karbach H, Klimkowska M, Hägglund H
Medical oncology (Northwood, London, England) 2012;29(2):1231-6

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
Hjorth M, Hjertner Ø, Knudsen Lm, Gulbrandsen N, Holmberg E, Pedersen Pt, et al
European journal of haematology 2012;88(6):485-96

Acquired hemophagocytic lymphohistiocytosis associated with multiple myeloma
Machaczka M, Vaktnas J, Klimkowska M, Nahi H, Hagglund H
MEDICAL ONCOLOGY 2011;28(2):539-43

A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma - Preliminary Safety Data
Gimsing P, Plesner T, Nahi H, Lokhorst H, Valentin Ml, Lisby S, et al
BLOOD 2011;118(21):817-817

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells
Ali D, Jonsson-videsater K, Deneberg S, Bengtzen S, Nahi H, Paul C, et al
EUROPEAN JOURNAL OF HAEMATOLOGY 2011;86(3):206-15

Clinical impact of chromosomal aberrations in multiple myeloma
Nahi H, Sutlu T, Jansson M, Alici E, Gahrton G
JOURNAL OF INTERNAL MEDICINE 2011;269(2):137-47

Follow-up of Real Life Treated Multiple Myeloma Patients: Response, Disease Progression and Overall Survival
Nahi H, Liwing J, Uttervall K, Andreasson J, Gruber A, Nasman P, et al
BLOOD 2011;118(21):1683-1683

Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective
Ludwig H, Beksac M, Blade J, Cavenagh J, Cavo M, Delforge M, et al
ONCOLOGIST 2011;16(4):388-403

Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks
Deneberg S, Guardiola P, Lennartsson A, Qu Y, Gaidzik V, Blanchet O, et al
BLOOD 2011;118(20):5573-82

Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor
Sutlu T, Stellan B, Gilljam M, Quezada Hc, Nahi H, Gahrton G, et al
CYTOTHERAPY 2010;12(8):1044-55

Constitutional inv(3) in myelodysplastic syndromes
Gahrton C, Nahi H, Jansson M, Wallblom A, Alici E, Sutlu T, et al
LEUKEMIA RESEARCH 2010;34(12):1627-9

Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia
Deneberg S, Grovdal M, Karimi M, Jansson M, Nahi H, Corbacioglu A, et al
LEUKEMIA 2010;24(5):932-41

Global and HOX Gene DNA Methylation In Normal Karyotype Acute Myeloid Leukemia: Clinical Implications and Molecular Correlations
Deneberg S, Lennartsson A, Uggla B, Gaidzik V, Corbacioglu A, Nahi H, et al
BLOOD 2010;116(21):107-107

OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AL-AMYLOIDOSIS IN SWEDEN
Rosengren S, Ahlberg L, Forsberg K, Lenhoff S, Mellqvist U, Nahi H, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2010;:393-393

ABCB1 SINGLE NUCLEOTIDE POLYMORPHISMS IN DE NOVO AML WITH NORMAL KARYOTYPE - IMPLICATIONS ON DRUG RESISTANCE AND SURVIVAL
Paul E, Lotfi K, Falk Ij, Rosenquist R, Paul C, Nahi H, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2009;:235-235

Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation
Paul E, Sutlu T, Deneberg S, Alici E, Bjorkstrand B, Jansson M, et al
ONCOLOGY REPORTS 2009;22(1):137-42

Implications On Drug Resistance and Survival of ABCB1 Single Nucleotide Polymorphisms in Normal Karyotype De Novo AML
Paul C, Green H, Falk Ij, Lotfi K, Paul E, Hermansson M, et al
BLOOD 2009;114(22):1038-1039

Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
Mellqvist Uh, Westin J, Gimsing P, Hjertner O, Lenhoff S, Laane E, et al
BLOOD 2009;114(22):221-221

In Vitro and Ex Vivo Studies On Cell Lines and Primary Human Leukemia Cells of the Effects of APR-246 Alone and in Combination with Conventional Chemotherapeutic Drugs.
Jonsson-videsater K, Ali D, Nahi H, Bengtzen S, Deneberg S, Paul C, et al
BLOOD 2009;114(22):1075-1076

Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival
Paul E, Uggla B, Deneberg S, Bengtzen S, Hermansson M, Dahlman I, et al
LEUKEMIA & LYMPHOMA 2009;50(9):1512-8

The prognostic significance of 8p21 deletion in multiple myeloma
Sutlu T, Alici E, Jansson M, Wallblom A, Dilber Ms, Gahrton G, et al
BRITISH JOURNAL OF HAEMATOLOGY 2009;144(2):266-8

An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients
Nahi H, Hagglund H, Ahlgren T, Bernell P, Hardling M, Karlsson K, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2008;93(11):1734-8

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components
Alici E, Sutlu T, Bojrkstrand B, Gilljam M, Stellan B, Nahi H, et al
BLOOD 2008;111(6):3155-62

Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia
Nahi H, Lehmann S
LEUKEMIA & LYMPHOMA 2008;49(3):508-16

Different Incidence and Implications of DNA Hypermethylation in De Novo AML Compared to High-Risk MDS and AML Following MDS
Deneberg S, Grovdall M, Jansson M, Gaidzik Vi, Corbacioglu A, Nahi H, et al
BLOOD 2008;112(11):1146-1147

Ex vivo expanded autologous natural killer cells as a novel therapeutic approach in multiple myeloma
Alici E, Sutlu T, Bjokstrand B, Gilljam M, Stellan B, Nahi H, et al
HUMAN GENE THERAPY 2008;19(10):1183-1183

Low Expression of p14(ARF) in De Novo AML with Normal Karyotype Is Associated with Short Survival but Increased in Vitro Sensitivity to p53 Modulating Drugs
Paul E, Uggla B, Wiman Kg, Paul C, Lehmann S, Nahi H
BLOOD 2008;112(11):1010-1010

Mutated and non-mutated TP53 as targets in the treatment of leukaemia
Nahi H, Selivanova G, Lehmann S, Mollgard L, Bengtzen S, Concha H, et al
BRITISH JOURNAL OF HAEMATOLOGY 2008;141(4):445-53

The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia
Mollgard L, Deneberg S, Nahi H, Bengtzen S, Jonsson-videsater K, Fioretos T, et al
CANCER CHEMOTHERAPY AND PHARMACOLOGY 2008;62(3):439-48

Transmission of chronic lymphocytic leukaemia from a blood stem cell sibling donor to the recipient
Nahi H, Jansson M, Sander B, Ljungman P, Hagglund H
BRITISH JOURNAL OF HAEMATOLOGY 2008;143(5):751-3

Transmission of CLL from a blood stem cell sibling donor to the recipient
Nahi H, Jansson M, Sander B, Ljungman P, Hagglund H
BONE MARROW TRANSPLANTATION 2008;:S196-S196

Expression of p14ARF in de novo AML with normal karyotype. Implication on drug resistance and survival
Paul Eo, Deneberg S, Lehmann S, Bengtzen S, Nahi H
BLOOD 2007;110(11):133B-133B

Topoisomerase II alpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia
Uggla B, Tina E, Nahi H, Paul C, Hoglund M, Sirsjo A, et al
INTERNATIONAL JOURNAL OF ONCOLOGY 2007;31(1):153-60

Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens
Swedish Grp Myeloproliferative Dis, Merup M, Lazarevic V, Nahi H, Andreasson B, Malm C, et al
BRITISH JOURNAL OF HAEMATOLOGY 2006;135(3):367-73

PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion
Nahi H, Merup M, Lehmann S, Bengtzen S, Mollgard L, Selivanova G, et al
BRITISH JOURNAL OF HAEMATOLOGY 2006;132(2):230-6

RITA activates p53 function in chronic lymphocytic leukaemia cells and induces apoptosis.
Nahi H, Merup M, Mollgard L, Selivanova G, Paul C
BLOOD 2005;106(11):472B-472B

Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study
Ljungman P, Nahi H, Linde A
BRITISH JOURNAL OF HAEMATOLOGY 2005;130(1):96-8

Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion
Nahi H, Lehmann S, Mollgard L, Bengtzen S, Selivanova G, Wiman Kg, et al
BRITISH JOURNAL OF HAEMATOLOGY 2004;127(3):285-91

PRIMA-1, a reactivator of mutant p53, induces antileukemic effects in cells from patients with chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
Nahi H, Merup M, Lehmann S, Mollgard L, Wiman C, Paul C
BLOOD 2003;102(11):604A-605A

Show all publications